The FDA accepts for review Epizyme’s (NASDAQ:EPZM) marketing application seeking approval to use tazemetostat to treat metastatic or locally advanced epitheloid sarcoma not eligible for curative surgery. The agency’s action date is January 23, 2020.
Epitheloid sarcoma is a rare slow-growing type of soft tissue cancer that typically starts under the skin of a finger, hand, forearm, lower leg or foot.
The company will host a conference call this morning at 8:30 am to discuss the filing.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.